DNMT3A and leukemia: To verify that an increase of ST2+ Treg cells and KLRG1+ST2+ Treg cells occur in leukemic samples from murine immunocompetent models of AML as well, a DNMT3A/FLT3ITD leukemic model28 was employed and examined in three different stages, pre-leukemia (~1 month), intermediate leukemia (~3 months), and advanced leukemia (~5 months) (Fig. 1C).